First Trust Advisors’s Intellia Therapeutics NTLA Stock Holding History

First Trust Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.75M	Buy	+339,807	New	+$4.76M	﹤0.01%	1504
2026 Q1	–	Sell	-276,855	Closed	-$2.49M	–	2691
2025 Q4	$2.49M	Buy	276,855 +266,179	+2,493%	+$3.66M	﹤0.01%	1779
2025 Q3	$184K	Buy	10,676 +448	+4%	+$5.52K	﹤0.01%	2514
2025 Q2	$95.9K	Buy	+10,228	New	+$84K	﹤0.01%	2571
2024 Q2	–	Sell	-51,438	Closed	-$1.42M	–	2395
2024 Q1	$1.42M	Buy	+51,438	New	+$1.43M	﹤0.01%	1870
2023 Q4	–	Sell	-33,208	Closed	-$1.05M	–	2403
2023 Q3	$1.05M	Buy	+33,208	New	+$1.29M	﹤0.01%	1947
2022 Q1	–	Sell	-71,282	Closed	-$8.43M	–	2572
2021 Q4	$8.43M	Buy	71,282 +5,826	+9%	+$730K	0.01%	1124
2021 Q3	$8.78M	Sell	65,456 -4,895	-7%	-$741K	0.01%	1044
2021 Q2	$11.4M	Sell	70,351 -24,946	-26%	-$1.94M	0.01%	962
2021 Q1	$7.65M	Buy	95,297 +25,283	+36%	+$1.7M	0.01%	1035
2020 Q4	$3.81M	Buy	+70,014	New	+$2.54M	0.01%	1233
2019 Q1	–	Sell	-67,322	Closed	-$919K	–	2441
2018 Q4	$919K	Sell	67,322 -92,981	-58%	-$1.73M	﹤0.01%	1864
2018 Q3	$4.59M	Buy	160,303 +55,798	+53%	+$1.62M	0.01%	1193
2018 Q2	$2.86M	Buy	+104,505	New	+$2.53M	0.01%	1412

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

First Trust Advisors's NTLA Position: Q2 2026 in Review

First Trust Advisors opened a new position in Intellia Therapeutics (NTLA) in Q2 2026: 339,807 shares worth $5.75M. The stake represents ﹤0.01% of the portfolio and ranks #1504 among its holdings. This is a return to the name: First Trust Advisors previously reported a position in NTLA as recently as Q4 2025.

First Trust Advisors first reported a position in NTLA in Q2 2018 and has held it in 14 quarters since. The position peaked at $11.4M in Q2 2021. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

First Trust Advisors held 339,807 shares of Intellia Therapeutics worth $5.75M as of Q2 2026.
Intellia Therapeutics was a new First Trust Advisors position in Q2 2026.
Intellia Therapeutics made up ﹤0.01% of First Trust Advisors's portfolio in Q2 2026, its #1504 holding.
First Trust Advisors first reported a position in Intellia Therapeutics in Q2 2018 and has held it in 14 quarters since.
First Trust Advisors's Intellia Therapeutics position peaked at $11.4M in Q2 2021.
329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.